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Abstract
Objectives To compare breast density measured on digital breast tomosynthesis (DBT) (BI-RADS-based breast composition and
fully-automatic estimation) and magnetic resonance imaging (MRI) (BI-RADS amount of fibroglandular tissue), and to evaluate
the diagnostic performance in terms of sensitivity and specificity of DBT and MRI in a predominantly dense breast population.
Methods Between 2015 and 2016, 152 women with 103 breast malignancies, who underwent 3-T breast MRI and DBTwithin 2
months’ time, were enrolled in this study. Breast composition/fibroglandular tissue and findings on DBT (two readers) and MRI
were reported using BI-RADS 5th edition. Digital mammography images were analysed for breast percent density (PD) using the
Libra software tool.
Results A majority of women had dense breasts as categorised by breast composition c (heterogeneously dense) (68%) and d
(extremely dense) (15%). The mean PD was 44% (range, 18-89%) and the correlation between breast composition and PD was r
= 0.6. The diagnostic performance of MRI was significantly higher compared to DBT for one reader as described by the area
under the receiver operating characteristic (ROC) curve (p = 0.004) and of borderline significance for the other reader (p = 0.052).
Conclusions MRI had higher diagnostic performance than DBT in a dense breast population in the tertiary setting.
Key Points
• MRI had higher diagnostic performance than DBT in a dense breast population
• Diagnostic performance of DBT was comparable to MRI in women with fatty breasts
• MRI was superior to DBT in preoperative breast cancer size assessment
Keywords Breast cancer .Breastdensity .Digital breast tomosynthesis .Magnetic resonance imaging .Diagnostic techniquesand
procedures
Abbreviations




BPE Background parenchymal enhancement
FN False negative
NST No special type
DCIS Ductal carcinoma in situ
ILC Invasive lobular carcinoma
FP False positive
Introduction
Digital breast tomosynthesis (DBT) has gained increasing in-
terest in the clinic for routine everyday use, with several early
clinical studies showing superior accuracy compared to that of
mammography [1–3]. Large multicentre studies have shown
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general benefits of DBT over digital mammography (DM),
but the role of tomosynthesis in women with dense breasts
has not yet been fully established [4–6]. Prospective trials of
screening a population from Europe show a statistically sig-
nificant increase in cancer detection rate with DBT (with or
without combined DM) compared with two-view DM inde-
pendent of vendor system [7–9]. Skaane et al. [7] stated:
BNotably, the additional cancers detected with mammography
plus tomosynthesis were distributed across all breast densities,
including fatty breasts^. Lång et al. [9] reported that the addi-
tional cancers were detected both in women with dense and
fatty breasts, drawing the conclusion that in mammography
even a moderate amount of breast tissue can conceal a small
lesion.
Breast cancer risk increases with increasing breast density
[10, 11]. The relationship holds true also for Japanese women
[12, 13], who are known to have dense breasts [14] and
highest age-specific breast cancer incidence at age 45–49
[15]. Breast density has until recently been classified qualita-
tively by use of the four categories in the ACR Breast Imaging
Reporting and Data System (BI-RADS) coding system: (1)
almost entirely fat (<25% fibroglandular tissue), (2) scattered
fibroglandular densities (25-50% fibroglandular tissue), (3)
heterogeneously dense (51-75% fibroglandular tissue) and
(4) extremely dense (>75% fibroglandular tissue) [16].
Recent revision of BI-RADS concerns changes to category
3: the breasts are heterogeneously dense, which may obscure
small masses, and discourage the use of a cut-off based on
percent density [17]. In order to more objectively assess breast
density and to reduce interobserver and intraobserver variabil-
ity, quantitative measurements have been developed [18, 19].
Both qualitative and quantitative methods of measuring breast
density have shown an association between high breast den-
sity and breast cancer risk [11, 20].
More than half of the USA states have begun legislating
mammographic breast density reporting to women, requiring
that women be notified of breast density with their mammog-
raphy results [21]. As a result, the U.S. Preventive Service
Task Force conducted a review of supplemental screening
for breast cancer in women with dense breasts and concluded
that density ratings may be recategorised on serial screening
mammography and, with limited evidence, that additional im-
aging with DBT reduces recall rates in women with dense
breasts; however, it was not clear the results implied fewer
overall breast biopsies [22].
Dynamic contrast-enhanced breast (DCE) MRI has excel-
lent sensitivity independent of breast density but still moderate
specificity [22, 23]. By adding diffusion-weighted imaging
(DWI) sequences, there is optimism to increase the specificity
[24]. Recommended indications for DCE MRI on defined
subgroups include: screening of high-risk women due to can-
cer susceptibility genes or greater than 20% lifetime risk of
developing breast cancer, assessment of occult primary breast
cancer, preoperative staging and evaluation of neoadjuvant
therapy [25, 26]. MRI is expensive and time-consuming,
hence the use of MRI in the clinic varies mainly due to
accessibility.
The purpose of this study was to compare breast density
measured on DBT and MRI, and to evaluate the diagnostic
performance in terms of sensitivity and specificity of DBTand
MRI in a predominantly dense breast population in the tertiary
setting.
Materials and methods
Patient population and lesions
Approval was obtained from the Institutional Review
Board of our institution with a waiver of informed consent
due to the retrospective nature of the study. Between
March 2015 and March 2016, a total of 494 patients
underwent 548 MRI examinations and 2,164 patients
underwent 2,292 DBT examinations at the Department of
Radiology, Kyoto University Hospital, Japan. The inclu-
sion criteria included matched MRI/DBT patient examina-
tions within 2 months’ time (n = 249) and BI-RADS diag-
nostic category 3, 4 or 5 on MRI, resulting in 162 patients.
Of these, 10 were excluded from analysis because of pre-
vious breast surgery (n = 5), incomplete MRI examination
(n = 2), insufficient follow-up (n = 2) or Paget’s disease (n
= 1). In total, 152 female patients (mean age, 57.1 ± 13.8
years; range, 28-83 years), of which 56 were healthy and
96 presented with 103 breast malignancies including 4 bi-
lateral and 3 multicentric, were enrolled in this study. All
breast cancer diagnoses were verified by surgery and/or
biopsy. Patients were considered healthy after negative sur-
gery and/or biopsy or at least 1-year negative imaging
follow-up on digital mammography and ultrasound (US)
and/or MRI. The MRI sample represented 31% (152/494)
and the DBT sample 7% (152/2,164) of the total number of
women being examined during the actual period of time.
MRI was performed on average 8.7 ± 10.6 days (range, -46
to 50 days) after DBT.
All women referred for clinical assessment during the time
period of the study had DBT as part of their examination,
unless contraindicated or DBTwas recently acquired at anoth-
er hospital. Indications for MRI in this study population were
mostly problem solving (n = 130; 85.5%) with the following
details: suspicious finding by DM (n = 29; 19.1%), suspicious
finding by US (n = 59; 38.8%), suspicious finding by DM and
US (n = 31; 20.4%), suspicious finding by computed tomog-
raphy (n = 11; 7.2%). Other indications included high-risk
women (n = 2; 1.3%) and preoperative staging (n = 20;
13.2%).
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Imaging acquisition
All patients included underwent bilateral two views
(craniocaudal and mediolateral oblique) using a full-field
DM unit with tomosynthesis capability (Selenia Dimensions;
Hologic, Bedford, MA, USA) operating in combo mode: DM
and DBT images were obtained within a single breast com-
pression for each projection. W/Rh and W/Al were used as
anode/filter combinations for DM and DBT, respectively, au-
tomatic exposure control was employed and 15 low-dose im-
ages were acquired during the X-ray movement over an angu-
lar range of 15°. These low-dose images were reconstructed
into millimetre-thin slices of the breast using filtered back-
projection. The mean compressed breast thickness was 34.4
± 12.6 mm (range, 8.5-73.5 mm).
The MRI examinations were performed with a 3.0-T scan-
ner (MAGNETOM Trio, A Tim System; Siemens, Erlangen,
Germany) with 16/4 channel breast coil. The parameters were
as follows: T2-weighted images (whole breast; axial orienta-
tion; 2D-turbo spin echo with fat suppression; repetition
time/echo time (TR/TE), 5,500/70 ms; field-of-view (FOV),
330 × 330 mm; matrix, 448 × 336; thickness, 3.0 mm), T1-
weighted images (whole breast; axial orientation; 3D volu-
metric interpolated breath-hold examination (3D-VIBE); TR/
TE, 4.95/2.46 ms; FOV, 330 × 330 mm; matrix, 480 × 398;
thickness, 1.5 mm), T1-weighted DCE images scanning at
pre-contrast state and at 0–1, 1–2 and 5–6 min after gadolin-
ium injection (whole breast; axial orientation; 3D-VIBE with
fat suppression; TR/TE, 3.95/1.43 ms; flip angle (FA), 15°;
FOV, 330 × 330 mm; matrix, 384 × 346; thickness, 1.0 mm),
contrast-enhanced T1-weighted images in high spatial resolu-
tion at 2–4.5 min after gadolinium injection (whole breast;
coronal orientation; 3D-VIBE with fat suppression; TR/TE,
4.61/1.81 ms; FA, 15°; FOV, 330 × 330 mm; matrix, 512 ×
461; thickness, 0.8 mm). TheMR examination was performed
during first half of the menstrual cycle in premenopausal
women and without scheduling limitations in postmenopausal
women.
Image interpretation and analysis
Two breast radiologists (M.I. and M.K. with 10 and 18 years
of experience in mammography, respectively) reviewed and
assessed the DBT images according to BI-RADS 5th edition
on a dedicated workstation unaware of any clinical informa-
tion or the histopathology diagnosis [17]. Breast composition
(based on mammography projections) and findings on DBT
were characterised and recorded. BI-RADS categories 1-3
were considered benign, and BI-RADS categories 4 and 5
were considered malignant. The MR images were assessed
and approved at the time of clinical interpretation by one of
two specialised breast radiologists (M.K. and S.K.) in accor-
dance with BI-RADS. Fibroglandular tissue (FGT),
background parenchymal enhancement (BPE), findings and
enhancement characteristics, including kinetic curve assess-
ment, were characterised and recorded. The software package
LIBRA, a fully-automatic breast density estimation software
solution, was used in this study to estimate the percentage
breast density (PD) [27, 28]. The average PD of the four
DM images was calculated and in cases containing larger
(>30 mm) invasive tumours, only the average of the contra-
lateral values was used (the size cut-off was chosen not to
exceed the natural dense breast tissue variation between the
two breasts, data not shown).
A preoperative tumour size assessment was performed by
retrospectively measuring the largest lesion diameter to the
nearest millimetre at the central core on both DBT and MR
images to establish which imaging modality most accurately
corresponds with the size of the pathology report [29, 30].
Tumours were classified as not measurable in cases of archi-
tectural distortion without definable borders or in cases where
the tumour was partially obscured by dense tissue onDBTand
in cases of multiple or diffuse enhancement patterns (mostly
classified as non-mass enhancement) within the breast on
MRI. Only invasive cancers were included in the analysis.
Statistical analysis
Inter-rater reliability was measured using percent agreement
and weighted kappa statistics. Pearson’s r and Spearman’s ρ
were used to test for correlations for normally and skewed
distributed data, respectively. One-way analysis of variance
with Bonferroni correction was used to compare PD means
between groups. Diagnostic performance was assessed with
receiver operating characteristics (ROC) curve analysis [31].
Area under the curve (AUC) was calculated from both para-
metric and trapezoidal curve fitting. Fisher’s exact test and
logistic regression analysis were performed to determine
which variables are associated with false negative (FN) out-
comes. Size agreement between imaging modality and pathol-
ogy measurements were analysed following the approach of
Bland and Altman. All analyses were performed using the
SPSS software (version 24; IBM Corp., Armonk, NY, USA)
and p values <0.05 were considered statistically significant.
Results
Out of all 103 breast cancers, 64 were invasive carcinoma of
no special type (NST), 26 ductal carcinoma in situ (DCIS), 6
invasive lobular carcinoma (ILC), 4 mucinous carcinoma, 1
micropapillary carcinoma, 1 tubular carcinoma and 1 apocrine
carcinoma.
The average percentage distribution of breast composition
(based on DBT) was: 2.3% (n = 3.5) category a, 15.5% (n =
23.5) category b, 67.8% (n = 103) category c, 14.5% (n = 22)
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category d. There was substantial inter-rater agreement be-
tween the two readers (R1 and R2) with percent agreement
of 85% (129/152) and weighted κ = 0.74 [95% confidence
interval (CI), 0.64-0.84].
The percentage distribution of amount of FGT (based on
MRI) was: 5.9% (n = 9) a. Almost entirely fat, 30.3% (n = 46)
b. Scattered fibroglandular tissue, 53.3% (n = 81) c.
Heterogeneous fibroglandular tissue, 10.5% (n = 16) d.
Extreme fibroglandular tissue.
The percentage distribution of background parenchymal
enhancement (BPE) level (based on MRI) was: 22.1% (n =
31) minimal, 32.1% (n = 45) mild, 26.4% (n = 37) moderate,
19.3% (n = 27) marked.
The mean PD was 43.5% (range, 18.3-88.6%). The aver-
age mean PD for the different breast compositions was: a =
23.4% (range, 18.3-26.4%), b = 31.7% (range, 18.8-51.5%), c
= 42.4% (range, 18.8-88.6%) and d = 64.8% (range, 41.1-
84.3%) (Fig. 1). All category means were significantly differ-
ent (p < 0.009), except for a with b (p = 1.00).
The correlations between breast composition, FGT, BPE
and PD ranged from weak to strong (Table 1).
On DBT, R1 had a sensitivity of 80.6% (FN = 20) and
positive predictive value (PPV) of 76.1% (FP = 26) and R2
had a sensitivity of 82.5% (FN = 18) and PPVof 74.6% (FP =
29). The AUC of the parametric ROC curve was 0.875 (95%
CI, 0.801-0.927) and 0.906 (95% CI, 0.852-0.944), and the
AUC of the trapezoidal ROC was 0.872 (95% CI, 0.823-
0.920) and 0.886 (95% CI, 0.841-0.930) for R1 and R2, re-
spectively (Fig. 2). MRI had a sensitivity of 97.1% (FN = 3)
and PPV of 62.5% (FP = 60). The AUC of the parametric
ROC curve was 0.964 (95% CI, 0.931-0.983) and the AUC
of the trapezoidal ROCwas 0.922 (95%CI, 0.893-0.952). The
Fig. 1 BI-RADS breast
composition categories with
corresponding breast percent
density as estimated by Libra




0.53 (0.40-0.64) 0.28 (0.11-0.45) 0.57 (0.46-0.67)
Breast composition
Reader 2
0.54 (0.41-0.65) 0.28 (0.09-0.44) 0.63 (0.53-0.72)
FGT 0.37 (0.22-0.53) 0.51 (0.38-0.63)
BPE 0.37 (0.22-0.51)
Numbers in parenthesis are 95% CIs
FGT fibroglandular tissue, BPE background parenchymal enhancement, PD percent density
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diagnostic performance of MRI was significantly higher com-
pared to DBT for R1 using the parametric model (p = 0.004)
and borderline higher compared to DBT for R2 (p = 0.052).
R2 rated one false positive (FP) as BI-RADS 5 on DBT and
one case of FP was rated as BI-RADS 5 onMRI. Twenty-five
percent (n = 5) and 33% (n = 6) of the FN on DBTwere rated
as BI-RADS 3 by R1 and R2, respectively, and 33% (n = 1) of
the FN on MRI was rated as BI-RADS 3.
By substituting MRI with DBT for women with mammog-
raphy breast composition category a or b, the MRI FP could
be reduced on average by 6% (R1, n = 4, R2, n = 3) at the cost
of a 1% average reduced sensitivity (R1, n = 0; R2, n = 2). By
applying PD threshold (<23.5%), a FP decrease of 3% (R1, n
= 2; R2, n = 2) can be achieved at no sensitivity loss.
Patient characteristics
In general, FP were highly correlated on the two systems, 77%
(20/26, R1) and 76% (22/29, R2).
No patient characteristics, including PD, were associated
with FN on DBT (Table 2). When dichotomised as fatty (cat-
egory a + b) or dense (category c + d), breast composition
suggested an association with FN on DBT, although not
reaching statistical significance, for R1 (p = 0.080). There
was no association with FN on DBT for R2 (p = 0.366). No
FN on DBTwas found in category a or b for R1 and two FNs
in category b (rated as c by R1) for R2. The lowest PD en-
countered for an FN was 23.5% for both readers.
The three FN cases on MRI were as follows: 45-year-old
woman with heterogeneous fibroglandular tissue and marked
BPE presenting DCIS, BI-RADS 1 (BI-RADS 4 on DBT by
both readers), 56-year-old woman with scattered
fibroglandular tissue and mild BPE, presenting DCIS, BI-
RADS 2 (BI-RADS 4 on DBT by both readers) and 37-
year-old woman with heterogeneous fibroglandular tissue
and marked BPE presenting a 15-mm, grade 1, luminal a,
mucinous carcinoma, BI-RADS 3 (BI-RADS 1 on DBT by
both readers) (Fig. 3). Due to the low number of FNs on MRI
no statistical tests were performed.
Lesion characteristics
The mean size 13.2 mm and 11.8 mm of FN was significantly
smaller than the mean size 20.6 mm and 21.2 mm of TP on
DBT for one reader (R1, p = 0.115 and R2, p = 0.041). No
other cancer characteristics were associated with FN by any
reader (p > 0.05); however, there was a trend for lobular his-
tological type being missed (Table 2).
Of the 77 invasive masses, 12 underwent neoadjuvant che-
motherapy and 1 case metastasised, leaving 64 masses with a
pathological mean size of 18.3 mm (median, 15 mm; range, 1-
65 mm). DBT could measure the invasive part in 57.8% (37/
64) and MRI in 89.1% (57/64) of the cases with size correla-
tion r = 0.73 and r = 0.78 versus pathology, respectively. One
reason for the low DBT percentage was because of the high
proportion of masses identified only by the calcification com-
ponent (n = 11) without size comparison to pathology.
Figure 4 shows the size deviations of the tumours measured
with DBTand MRI compared with the averages of the pathol-
ogy and said modality, respectively.
Discussion
The diagnostic performance of MRI was significantly higher
compared to DBT for one reader (p = 0.004) and of borderline
significance for the other reader (p = 0.052). Only a few stud-
ies have compared the diagnostic performance of DBT versus
MRI in specific settings [32–35]. Kim et al. [35] reported
higher diagnostic performance (sensitivity, 97.8%) but lower
PPV (89.6%) for MRI versus DBT (sensitivity, 88.2%; PPV,
93.3%), which is in line with the results of this study. Clauser
Fig. 2 ROC curves for DBT and
MRI. Solid lines parametric
model, dashed lines trapezoidal
model
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Table 2 Univariate associations of patient and lesion characteristics with false negatives on DBT
Patient characteristics True positive False negative Significancea
R1 R2 R1 R2 R1 R2
Age OR = 1.02 95% CI = 0.98-1.05 OR = 1.01 95% CI = 0.98-1.05 p = 0.334 p = 0.503
Breast composition p = 0.155 p = 0.649
a (fatty) 3 (2) 4 (3) 0 (0) 0 (0)
b 19 (14) 26 (19) 0 (0) 2 (11)
c 93 (71) 86 (64) 15 (75) 12 (67)
d (dense) 17 (13) 18 (13) 5 (25) 4 (22)
Breast composition p = 0.080 p = 0.366
a + b (fatty) 22 (17) 30 (22) 0 (0) 2 (11)
c + d (dense) 110 (83) 104 (78) 20 (100) 16 (89)
FGT p = 0.698 p = 0.763
a (fatty) 9 (7) 9 (7) 0 (0) 0 (0)
b 41 (31) 39 (29) 5 (25) 7 (39)
c 68 (52) 72 (54) 13 (65) 9 (50)
d (extreme) 14 (11) 14 (10) 2 (10) 2 (11)
BPE p = 0.558 p = 0.394
Minimal 28 (23) 28 (23) 3 (17) 3 (19)
Mild 37 (30) 39 (32) 8 (44) 6 (38)
Moderate 34 (28) 35 (28) 3 (17) 2 (13)
Marked 23 (19) 22 (18) 4 (22) 5 (31)
PD OR = 1.02 95% CI = 0.99-1.05 OR = 1.01 95% CI = 0.98-1.04 p = 0.277 p = 0.553
Breast thickness OR = 0.98 95% CI = 0.94-1.01 OR = 0.98 95% CI = 0.94-1.02 p = 0.205 p = 0.237
Lesion characteristics True positive False negative
Size OR = 0.95 95% CI = 0.90-1.02 OR = 0.93 95% CI = 0.87-1.00 p = 0.115 p = 0.041
Type of finding p = 0.266 p = 1.000
Invasive 64 (77) 63 (74) 13 (65) 14 (78)
In-situ 19 (23) 22 (26) 7 (35) 4 (22)
Histological type p = 0.190 p = 0.230
Ductal 55 (86) 54 (86) 9 (69) 10 (71)
Lobular 4 (6) 4 (6) 2 (15) 2 (14)
Other 5 (8) 5 (8) 2 (15) 2 (14)
Histological grade p = 0.810 p = 0.660
Grade 1 21 (33) 20 (32) 3 (23) 4 (29)
Grade 2 24 (38) 25 (40) 5 (39) 4 (29)
Grade 3 19 (30) 18 (29) 5 (39) 6 (43)
Subtypeb p = 0.854 p = 0.601
Luminal a 36 (56) 36 (57) 9 (69) 9 (64)
Luminal b HER2- 13 (20) 13 (21) 2 (15) 2 (14)
Luminal b HER2+ 6 (9) 6 (10) 0 (0) 0 (0)
HER2+ non-luminal 2 (3) 2 (3) 0 (0) 0 (0)
Triple negative 7 (11) 6 (10) 2 (15) 3 (21)
Numbers in parentheses are percentages
R reader, FGT fibroglandular tissue, BPE background parenchymal enhancement, PD percent density, OR odds ratio, CI confidence interval
a Logistic regression and Fisher’s exact test were used for continuous and discrete data, respectively
b St Gallen 2013 classification
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et al. [33] and Mariscotti et al. [34] investigated the role of
DBT as a so-called second-look modality for additional find-
ings at preoperative MRI, observing an increased detection
rate when adding DBT to US, although, still inferior to MRI.
Breast composition, although not statistically significant,
tend to be associated with FN on DBT (R1, p = 0.080) in
contrast to PD. Thus, a masking effect (particularly the use
of category c) seems to be prominent regardless of specific
percentage density thresholds. The moderate to strong corre-
lation between breast composition and PD also suggests this
finding. Since 68% of the women in this study were assigned
breast composition c, it would be of great interest to explore
any sub categorisation based on, for instance, parenchymal
distribution or texture.
The prospective screening trials have not shown a signifi-
cant cancer detection increase for DBT in category d, owing to
the low sample size; however, there was no significant detec-
tion increase in breast composition d for DBT compared with
DM alone in a multicentre study by Rafferty et al. [36], despite
a larger sample size [7–9]. This lack of evidence is the main
reason that DBT is still on hold as a complementary tool for
the screening of women with dense breasts [22].
Eighty-two percent of the study population had dense
breasts as categorised by breast compositions c and d and
the density distribution was also significantly different from
the anticipated 10%/40%/40%/10% by ACR BI-RADS in a
screening setting [17]. As a comparison, data from the Breast
Cancer Surveillance Consortium [37] showed that 43.3% of
the US women are considered dense. The distribution of PD,
as estimated by Libra within the radiologist-provided breast
composition categories (Fig. 1.), resembled those in the work
of Keller et al. [27], except for category c demonstrating a
broader range. This is likely a result of the adoption of the
newACRBI-RADS category c definition, taking into account
the masking effect. Comparing this Japanese study population
(mean age, 57 years) with black and white Pennsylvanian
women (n = 9,498; mean age, 57 years) regarding PD estima-
tions using Libra, the population in this study had more than
double PD, 44% versus 12.3% (black) and 17.1% (white)
[38]. Despite not being a screening population, this result sup-
ports the view that Japanese women have dense breasts [12].
The literature is sparse regarding correlation of qualitative
imaging assessments of FGT, BPE and mammographic breast
composition. Hansen et al. [39] found a correlation of 0.36
between BPE and mammographic breast composition com-
pared to 0.28 in this study. King et al. [40] found a non-
significant correlation for one reader and a significant corre-
lation of 0.4 for another between FGT and BPE, compared to
0.37 in this study. No studies were found correlating qualita-
tive FGTand mammographic breast composition, which were
consideredmoderate in this study (r = 0.53 and r = 0.54 for R1
and R2, respectively).
The preoperative size assessment was superior for MRI
compared to DBT, showing a stronger correlation and a better
size agreement with pathology (Fig. 4.). The DBT correlation
coefficient of 0.73 was a little lower compared with other
published studies: 0.86 by Förnvik et al. [29] and 0.86 by
Luparia et al. [30], which could be explained by the predom-
inantly dense breast population or the use of a narrow-angle
DBT system. Chudgar et al. [41] assessed the use of preoper-
ative MRI for disease extent in breast cancer detected at DBT
versus DM alone and found that women with fatty breasts
screened with DBT may benefit less from preoperative MRI
than women with more dense breasts. By applying a PD
threshold based on the FN, about 10% (13/137) of the study
Fig. 3 A 37-year-old woman with a 15-mm mucinous carcinoma in the
right breast and a benign fibroadenoma in the left breast. a Bilateral DBT
slices in the mediolateral oblique projection with the fibroadenoma
highlighted (arrow) in the left breast. Both readers reported breast
composition d and percent density was estimated to 70% by Libra. The
carcinoma was missed (BI-RADS 1) by both readers and the
fibroadenoma was rated BI-RADS 4 by reader 1 and BI-RADS 3 by
reader 2. b Axial post-contrast T1-weighted MRI with the carcinoma
highlighted in the right breast (arrow) and the fibroadenoma (arrowhead)
in the left breast. The amount of fibroglandular tissue was reported het-
erogeneous and the background parenchymal enhancement was marked.
The final report stated BI-RADS 3 finding in the right breast and BI-
RADS 4 finding in the left breast
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population could potentially undergo DBT instead of MRI
without any loss in sensitivity. Using breast composition
groups a and b would increase specificity at a slight cost of
sensitivity.
A limitation of the current study was the exclusion of BI-
RADS 1 and 2 cases because of the sporadic follow-up in
these groups, especially in the tertiary setting. Consequently,
this could bias PPV in favour of DBT and overestimate MRI
sensitivity. The relatively short minimum follow-up of 1 year
for negative cases not undergoing biopsy/surgery is also a
limitation of the current study. This study has followed the
recommendations of BI-RADS 5th edition; thus, care should
be taken when comparing the results with older BI-RADS
editions, particularly regarding the breast density classifica-
tion. The study population may also differ between a tertiary
setting and a non-tertiary setting with regard to breast cancer
profile and breast density. Another limitation was the final
decision-making by one breast specialist for the MRI interpre-
tation limiting the generalisation of the results. In addition,
priors were not read during DBT interpretation, which could
Fig. 4 Bland-Altman plot of
invasive tumour size measured by
pathology subtracted from that
measured by DBT (a) and MRI
(b) compared with the mean of
the two results. Middle dashed
line is the mean difference and top
and bottom dashed lines are the
95% limits of agreement (±2
standard deviations)
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lower the diagnostic performance. It was not within the scope
of this paper to compare the added value of DBT to DM alone.
In conclusion, DBT can be performed instead of MRI in
women with non-dense breasts as determined by either a PD
threshold or breast compositions a and b or in the case of MRI
contraindications. MRI has higher diagnostic performance
than DBT in a dense breast population in the tertiary setting.
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